Informed Consent for Egg Donors Won’t Exist Unless We Track Donors’ Health
By Judy E. Stern,
Our Bodies, Our Blog
| 10. 01. 2015
Both a recent article in the Journal of Law, Medicine & Ethics and a related Ob.Gyn. News story have raised concerns about the risks of egg donation and the process of providing informed consent for donors.
Despite guidelines from the American Society for Reproductive Medicine and the Society for Assisted Reproductive Technology, clinical and monetary pressures can create conflicts for providers of reproductive healthcare between the needs of the egg donors and those of the couples to whom their eggs are donated — both of whom are often patients of the same providers.
The articles raise concerns that these conflicts may result in donors having an incomplete understanding of the risks and ramifications of stimulation to produce multiple eggs and retrieval of those eggs for donation.
Egg donation is a commonly used assisted reproductive technology (ART) procedure accounting for more than 12 percent of ART cycles in the United States. Conflicts can arise on several levels: donor recruitment; screening, consent and disposition decisions; ovarian stimulation; and post-stimulation monitoring.
Recruitment can involve misleading advertisements, which may not accurately convey the...
Related Articles
By Emma Cieslik, Ms. Magazine | 11.20.2025
Several recent Biopolitical Times posts (1, 2, 3, 4) have called attention to the alarmingly rapid commercialization of “designer baby” technologies: polygenic embryo screening (especially its use to purportedly screen for traits like intelligence), in vitro gametogenesis (lab-made eggs and sperm), and heritable genome editing (also termed embryo editing or reproductive gene editing). Those three, together with artificial wombs, have been dubbed the “Gattaca stack” by Brian Armstrong, CEO of the cryptocurrency company...
By Adam Feuerstein, Stat | 11.20.2025
The Food and Drug Administration was more than likely correct to reject Biohaven Pharmaceuticals’ treatment for spinocerebellar ataxia, a rare and debilitating neurodegenerative disease. At the very least, the decision announced Tuesday night was not a surprise to anyone paying attention. Approval...
By Emily Glazer, Katherine Long, Amy Dockser Marcus, The Wall Street Journal | 11.08.2025
For months, a small company in San Francisco has been pursuing a secretive project: the birth of a genetically engineered baby.
Backed by OpenAI chief executive Sam Altman and his husband, along with Coinbase co-founder and CEO Brian Armstrong, the startup—called...